
Reset all filters
01 1Airsupra
02 1Combivent
03 6ProAir
04 2Proair
05 11Ventolin
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 274
2018 Revenue in Millions : 397
Growth (%) : -31
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,088
2019 Revenue in Millions : 1,300
Growth (%) : -16
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 241
2019 Revenue in Millions : 274
Growth (%) : -12
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 180
2020 Revenue in Millions : 241
Growth (%) : -25
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 972
2020 Revenue in Millions : 1,075
Growth (%) : -9
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 951
2021 Revenue in Millions : 972
Growth (%) : -2
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 808
2022 Revenue in Millions : 951
Growth (%) : -3
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 873
2023 Revenue in Millions : 808
Growth (%) : 8
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 66
2023 Revenue in Millions : 2
Growth (%) : 3,200
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : 11.40%
2013 Revenue in Millions :
Growth (%) :